Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for the Week Ending May 2, 2020

5/5/2020

 
Regulatory Update
 
The FDA approved opicapone (Ongentys, Neurocrine Bioscience) on 4/27/2020, as add-on therapy to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes.
 
The FDA accepted the NDA for terlipressin (Lucassin, Mallinckrodt, Biovie) to treat hepatorenal syndrome type 1 (HRS-1) and set a PDUFA date of 9/12/2020.
 
The EMA accepted the Marketing Authorization Application (MAA) for lonafarnib (Sarasar, Eiger BioPharmaceuticals, Merck) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies.
 
Chimerix began a rolling NDA for brincidofovir as a treatment for smallpox and expects to complete it by mid-2020.
 
Announced Research Updates
 
Roche announced that in the 12-month, 41 patient, Phase III, open-label FIREFISH trial, 29.3% (12/41) of infants treated with risdiplam were able to sit without support for at least five seconds, assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III) compared to none in a historical control cohort of infants with Type 1 spinal muscular atrophy.
 
Novartis announced that in the 97 patient, Phase II, Geometry mono-1 trial, treatment with capmatinib resulted in an overall response of 40.6% in the pre-treated group and 67.9% in the treatment-naive group in patients with metastatic MET exon 14 skipping non-small cell lung cancer. In 13 patients with brain metastases, 7/13 (54%) had an intracranial response with four patients having a complete resolution of all brain lesions.
 
Published Research Updates
 
In a 4-week, 1,432 patient, open label trial, 70.5% of patients treated with nabiximols had a decrease in at least one spasticity-related symptom in patients with multiple sclerosis drug-resistant spasticity. This observational study was performed in Italy, where the drug is already approved.
 
In a 48-week, 48 patient, phase II trial, treatment with ublituximab resulted in median B cell depletion of > 99%, a decrease in mean T2 lesion volume of 10%, and an annualized relapse rate of 0.07, with 93% of patients with relapsing multiple sclerosis being relapse free.
 
In the 25 patient, Phase II, open-label, PIKTAM trial, treatment with buparlisib plus tamoxifen resulted in a progression-free survival rate at 6-months of 33.3% in patients with hormone receptor-positive, HER2-negative advanced breast cancer previously treated with hormone therapy. The PIKTAM trial was originally designed to enroll 99 patients, but was terminated early due to liver toxicity observed in the BELLE-2 trial.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.